Low-calorie diets linked to surprising mental health effect, new research shows
A new study, published in BMJ Nutrition, Prevention and Health, investigated how the adoption of restrictive diets could instigate depressive symptoms.
Using the National Health and Nutrition Examination Survey, researchers analyzed nearly 29,000 adults who reported their dietary habits and also completed a mental health questionnaire.
Rates Of Dementia Are Lower In People Who Eat This Specific Diet, Research Shows
Nearly 8% of these adults reported depressive symptoms.
Compared to those who did not follow a specific diet, those who stuck to a calorie-restrictive diet — including overweight individuals — saw an increase in depressive symptom severity, the study found.
Read On The Fox News App
People who followed a nutrient-restricted diet saw a larger increase in symptoms, while men who followed any diet reportedly showed "higher somatic symptom scores" compared to non-dieters.
The researchers concluded that there are "potential implications of widely followed diets on depressive symptoms, and a need for tailored dietary recommendations based on BMI and sex."
Judith S. Beck, PhD, president of the Beck Institute for Cognitive Behavior Therapy in Pennsylvania, reacted to these findings in an interview with Fox News Digital.
The expert, who was not involved in the research, noted that it only showed an association between low-calorie diets and depression.
10 Best Diets Of 2025 As Chosen By Nutrition Experts
"This is an important distinction, [because] correlation does not equal causation, and having a few depressive symptoms does not mean you have the condition of depression," she said.
Beck noted that depression and negative emotions can also be caused by multiple cognitive, emotional or behavioral factors that are "more directly associated with depressive symptoms."
Certified holistic nutritionist Robin DeCicco in New York City commented that most Americans would benefit from losing weight, as 70% of Americans are overweight or obese, according to the Centers for Disease Control and Prevention (CDC).
This can be done by reducing the intake of sugary drinks and processed foods, and learning how to incorporate more whole foods like lean protein, vegetables, fruits and nuts, recommended DeCicco, who also was not involved in the study.
This Weight Loss Plan Performs Better Than Traditional Dieting, Study Finds
The nutritionist also warned against following fad diets.
"It's not sustainable or healthy to follow these trends because, most often, they are not educating the public on the type of nutrients you need to function mentally and physically, which is why it doesn't surprise me that people can experience depressive and cognitive-affective symptoms when losing weight."
The quality of calories "matters dramatically," DeCicco noted.
"While weight loss is about calories in and calories out, it's also about the type of calories and what we need for fuel, protection against disease, and mental and physical satisfaction," she said.
"Food has the power to help us or harm us, and if we're not eating certain foods known to promote mental well-being, we will definitely suffer from cognitive impairment and unstable mood."
As an example, cutting out fats because they're high in calories — like salmon, avocado, olive oil and nuts — also cuts out nutrients like omega-3 fatty acids, which can reduce inflammation, prevent disease and improve cognition, mood and brain health, DeCicco noted.
"If someone wants to lose weight but also has a health history of cognitive decline or is diagnosed with depression, it is even more important to emphasize the food groups mentioned above," DeCicco added.
Click Here To Sign Up For Our Health Newsletter
Beck echoed the importance of eating in a "very healthy way," while also recommending that people consider cognitive behavioral therapy (CBT).
For more Health articles, visit foxnews.com/health
"CBT helps people learn the cognitive (thinking) and behavioral skills they need to eat as healthily as possible given their circumstances, and to change their thinking so they can make long-term changes in their eating and improve their overall health," she said.
Fox News Digital reached out to the study researchers for comment.Original article source: Low-calorie diets linked to surprising mental health effect, new research shows
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
Accelerating Data Entry for Non-GLP Pathology Studies, Upcoming Webinar Hosted by Xtalks
In this free webinar, learn how streamlined workflows and intuitive interfaces help pathologists reduce time spent on slide review and data capture — freeing up hours for deeper analysis. Attendees will see how built-in checks, standardized terminology and smart glossaries reduce errors and ensure pathology data can be trusted throughout the study lifecycle. The featured speakers will share how efficient, flexible tools can support non-GLP pathology studies without sacrificing structure — helping study directors manage timelines, staff and results more effectively. TORONTO, Aug. 19, 2025 /PRNewswire/ -- Pathologists and study directors in nonclinical research are under increasing pressure to deliver high-quality results faster, without compromising data integrity. Traditional, manual methods of data entry are too slow, error-prone and unstructured to meet the demands of today's fast-paced, high-throughput labs. That's why modern pathology teams are turning to efficient, standardized digital tools to accelerate workflows, reduce human error and improve overall productivity in conducting non-GLP pathology studies. Another goal of an optimized pathology workflow is about transforming how non-GLP pathology studies are managed, recorded and scaled for future success. With smarter digital systems, labs can gain immediate efficiency while laying the groundwork for regulatory readiness down the road. In this webinar, the featured speakers will explore how pathology teams can modernize their approach to study management with tools designed specifically for fast, intuitive and reliable histopathology workflows. For teams aiming to optimize current non-GLP processes or prepare for future GLP compliance, this session will offer practical insights to support confident progress. Join the pathology experts as they demonstrate how digital tools and workflows can: Reduce slide review and data entry time by up to 20% using streamlined digital workflows built for non-GLP environments Improve data integrity and accessibility with structured study management tools offering a single source of truth for moderated access and editing. Streamline glossary management with integrated terminology support based on CDISC ontology and intelligent search features. Manage non-GLP studies more efficiently through flexible, user-friendly platforms that support better team coordination and faster study completion Prepare labs for future GLP compliance by adopting digital tools that align with industry standards and regulatory expectations Register for this webinar to learn how digital transformation can drive efficiency and readiness across pathology studies, supporting pathologists, study directors, lab managers and more. Join experts from Instem, Chris Nichols, Senior Director; and Chris Hunter, Product Manager, Pathology Study Management, for the live webinar on Friday, September 5, 2025, at 10am EDT (4pm CEST/EU-Central). For more information, or to register for this event, visit Accelerating Data Entry for Non-GLP Pathology Studies. ABOUT XTALKS Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers. To learn more about Xtalks visit For information about hosting a webinar visit Contact:Vera KovacevicTel: +1 (416) 977-6555 x371Email: vkovacevic@ View original content to download multimedia: SOURCE Xtalks Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 minutes ago
- Yahoo
Medtronic Lifts Annual Outlook, Appoints New Directors In Post-Elliott Strategic Shift
Medtronic plc (NYSE:MDT) announced key board appointments on Tuesday, naming John Groetelaars and Bill Jellison as independent directors, effective immediately. This move comes shortly after Elliott Investment Management became the company's largest shareholder. The company also unveiled its new Growth Committee, tasked with overseeing the evaluation and execution of strategic M&A, R&D investments, and potential divestitures, including the planned separation of its Diabetes business. The medtech giant is scheduled to host an Investor Day in mid-2026, as first reported by The Wall Street reported strong first-quarter 2026 results, with sales hitting $8.58 billion, surpassing the consensus estimate of $8.38 billion. This marks an 8.4% increase year-over-year, with organic growth of 4.8%. Adjusted earnings of $1.26 per share also beat expectations of $1.23. 'We're confident and well-positioned to accelerate our revenue growth in the second half of our fiscal year, as we make meaningful progress on our major growth drivers,' said Geoff Martha, Medtronic chairman and CEO. Cardiovascular Portfolio revenue of $3.285 billion increased 9.3% as reported and 7.0% organic, with a high-single digit increase in Cardiac Rhythm & Heart Failure, mid-single digit increase in Structural Heart & Aortic, and low-single digit increase in Coronary & Peripheral Vascular, all on an organic basis. Neuroscience Portfolio revenue of $2.416 billion increased 4.3% reported and 3.1% organic, with a high-single digit increase in Neuromodulation and mid-single digit increase in Cranial & Spinal Technologies, offset by a low-single digit decrease in Specialty Therapies. View more earnings on MDT Medical Surgical Portfolio revenue of $2.083 billion grew 4.4% as reported and 2.4% organic, with low-single digit organic growth in both Surgical & Endoscopy and Acute Care & Monitoring. Diabetes business revenue of $721 million increased 11.5% as reported and 7.9% organic. Outlook Medtronic reiterates its fiscal year 2026 organic revenue growth guidance of 5%. The company revised its fiscal 2026 revenue growth on a reported basis from 4.8%-5.1% to 6.5%-6.8%. It raised sales guidance from $35.15 billion-$35.25 billion to $35.72 billion-$35.82 billion versus the consensus of $35.32 billion. Excluding the potential impact from tariffs, Medtronic expects underlying fiscal 2026 adjusted EPS growth to be approximately 4.5% versus the prior guidance of approximately 4%. Including the reduced potential impact from tariffs of approximately $185 million versus the prior range of roughly $200 million to $350 million, Medtronic raised its fiscal 2026 adjusted earnings to $5.60-$5.66 from the prior range of $5.50-$5.60 versus the consensus of $5.55. In July, a federal appeals court sided with Medtronic in a long-running patent dispute, reversing a jury's finding that the company induced infringement of a Colibri Heart Valve LLC patent related to the implantation of artificial heart valves. Price Action: MDT stock is trading lower by 2.00% to $90.95 premarket at last check Tuesday. Read Next:Image via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? MEDTRONIC (MDT): Free Stock Analysis Report This article Medtronic Lifts Annual Outlook, Appoints New Directors In Post-Elliott Strategic Shift originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
36 minutes ago
- Yahoo
Twist Bioscience Launches Oncology DNA CGP Panel to Advance Precision Medicine with Customizable, Platform-Agnostic NGS Solution
SOUTH SAN FRANCISCO, Calif., August 19, 2025--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity, in the life sciences segment of the health care sector, today launched the Twist Oncology DNA Comprehensive Genomic Profiling (CGP) Panel, a customizable, research-use-only solution designed to empower users to identify genomic alterations for a broad set of tumors, guide targeted therapy development and support clinical and translational oncology research. "We designed this panel to break the status quo in genomic profiling by offering laboratories a powerful alternative to locked, one-size-fits-all solutions," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. "With our customizable content, flexible workflow, and compatibility with multiple sequencing platforms, Twist's Oncology DNA CGP Panel puts scientific control back in the hands of researchers and clinicians, particularly for those who need a more cost-effective solution compared to existing CGP products or a more efficient option than smaller panels." The Twist Oncology DNA CGP Panel was designed to serve a wide range of research groups including regional clinical labs, academic medical centers, and biopharma partners. The panel composition incorporates clinical research and includes a comprehensive and updated biomarker list covering 562 genes that incorporate all major tumor types. The panel's coverage spans genomic alterations and genomic signatures and can detect base substitutions, insertions and deletions (indels), copy number variations (CNVs), gene rearrangements as well as measure tumor mutational burden (TMB) and microsatellite instability (MSI). This is paired with Twist high quality and easy-to-use library preparation and target enrichment workflows. Twist is collaborating with several analytics companies to provide a complete solution from sequencing to analysis. About Twist Bioscience Corporation At Twist Bioscience, we work in service of customers who are changing the world for the better. In fields such as medicine, agriculture, industrial chemicals and defense, by using our synthetic DNA tools, our customers are developing ways to better lives and improve the sustainability of the planet. The faster our customers succeed, the better for all of us, and Twist Bioscience is uniquely positioned to help accelerate their efforts. Our innovative silicon-based DNA Synthesis Platform provides precision at a scale that is otherwise unavailable to our customers. Our platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis, sequencing and therapeutics discovery, providing both the quality and quantity of the tools they need to most rapidly realize the opportunity ahead. For more information about our products and services, please visit Follow us on LinkedIn | X | YouTube | Instagram | Bluesky Twist Bioscience Legal Notice Regarding Forward-Looking Statements This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements about the expected future benefits and impact of the Twist Oncology DNA CGP Panel and collaborations with analytics companies. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period; ability to obtain financing when necessary; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist is developing obsolete or non-competitive; ability to expand DNA synthesis manufacturing capacity; dependence on one supplier for a critical component; dependence on key personnel; additional regulations that could increase Twist's costs and delay commercialization efforts; changes in U.S. trade policies and other trade actions that could result in increased costs and supply chain disruptions; and the ability to maintain and enforce intellectual property protection. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist's business in general, see Twist's risk factors set forth in Twist's Annual Report on Form 10-K for the year ended September 30, 2024 filed with the Securities and Exchange Commission (SEC) on November 18, 2024 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. View source version on Contacts For Investors: Angela BittingSVP, Corporate Affairs925-202-6211abitting@ For Media: Amanda HoulihanCommunications Manager774-265-5334ahoulihan@